Sustained HCV clearance after hepatitis C therapy is associated with reduced liver-related complications and death. It is unknown if treatment may provide any clinical benefit in patients that fail therapy. This could be particularly relevant in HIV–HCV-coinfected patients, in whom liver disease progresses more rapidly.
Methods
This was a retrospective study of clinical end points in a large cohort of HIV–HCV-coinfected patients with compensated liver disease followed since 2004. Patients were stratified into three groups: treated and cured, treatment failures and non-treated. Follow-up ended at the time of last visit, first liver decompensation event or death.
Results
A total of 527 HIV–HCV-coinfected patients were examined, of whom 339 (64.3%) had been treated with pegylated interferon/ribavirin. During a mean follow-up of 70.5 months, hepatic decompensation events or liver-related deaths occurred less frequently in cured patients (4/138; 2.9%) than in treatment failures (28/201; 13.9%) or untreated (25/188; 13.3%) patients (P<0.001). Interestingly, in the subset of patients with baseline advanced liver fibrosis (Metavir F3–F4), those with treatment failure experienced less hepatic decompensation events or deaths than untreated patients (19% versus 42%; P=0.005) and this finding was more pronounced in patients harbouring IL28B-CC alleles (15.8% versus 47.4%; P=0.02).
Conclusions
Sustained HCV clearance following pegylated interferon/ribavirin therapy is associated with a reduced incidence of liver complications and death in HIV–HCV-coinfected patients. In the subset of patients with baseline advanced liver fibrosis, treatment provides clinical benefit despite lack of sustained virological response. The transient antiviral and/or anti-inflammatory effect of interferon, more recognizable in IL28B-CC carriers, could explain this finding.
References
1.
MalletV., GilgenkrantzH., SerpaggiJ.The relationship of regression of cirrhosis to outcome in chronic hepatitis C.Ann Intern Med2008; 149: 399–403.
2.
Fernández-MonteroJ.V., BarreiroP., VispoE.Liver fibrosis progression in HIV–HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy.Antivir Ther2014; 19: 287–292.
3.
VeldtB.J., HeathcoteE.J., WedemeyerH.Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.Ann Intern Med2007; 147: 677–684.
4.
van der MeerA.J., VeldtB., FeldJ.Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.JAMA2012; 308: 2584–2593.
5.
SorianoV., MaidaI., NúñezM.Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies.Antivir Ther2004; 9: 987–992.
6.
BerenguerJ., Alvarez-PellicerJ., MartínP.Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with HIV and hepatitis C virus.Hepatology2009; 50: 407–413.
7.
MacíasJ., BerenguerJ., JapónM.A.Fast fibrosis progression between repeated liver biopsies in patients coinfected with HIV/hepatitis C virus.Hepatology2009; 50: 1056–1063.
8.
KonermanM.A., MehtaS., SutcliffeC.Fibrosis progression in HIV/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs.Hepatology2014; 59: 767–775.
9.
ThomasD.L.Cure of hepatitis C virus infection without interferon alfa: scientific basis and current clinical evidence.Top Antivir Med2014; 21: 152–156.
10.
ShiffmanM.L., BenhamouY.HCV F1/2 patients: treat now or continue to wait.Liver Int2014; 34Suppl 1: 79–84.
11.
BarreiroP., Fernández-MonteroJ.V., de MendozaC., LabargaP., SorianoV.Towards hepatitis C eradication from the HIV-infected population.Antiviral Res2014; 105: 1–7.
12.
ThompsonM.A., AbergJ., HoyJ.Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.JAMA2012; 308: 387–402.
13.
Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.Department of Health and Human Services. (Accessed 5 March 2014.) Available from http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.
14.
European AIDS Clinical Society (EACS).Guidelines version 7.1 (October 2013). (Accessed 5 March 2014.) Available from www.europeanaidsclinicalsociety.org.
15.
de LédinghenV., DouvinC., KettanehA.Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients.J Acquir Immune Defic Syndr2006; 41: 175–179.
16.
CrowellT.A., GeboK., BalagopalA., FleishmanJ., AgwuA., BerryS.Impact of hepatitis coinfection on hospitalization rates and causes in a multicenter cohort of persons living with HIV.J Acquir Immune Defic Syndr2014; 65: 429–437.
17.
LinasB.P., WangB., SmurzynskiM.The impact of HIV/ HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort.J Viral Hepat2011; 18: 506–512.
18.
CastellaresC., BarreiroP., Martín-CarboneroL.Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome.J Viral Hepat2008; 15: 165–172.
19.
GrahamC.S., BadenL., YuE.Influence of HIV infection on the course of hepatitis C virus infection: a meta-analysis.Clin Infect Dis2001; 33: 562–569.
20.
LimketkaiB.N., MehtaS., SutcliffeC.Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV.JAMA2012; 308: 370–378.
21.
BerenguerJ., Alvarez-PellicerJ., CarreroA.Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with HIV and hepatitis C virus.J Hepatol2013; 58: 1104–1112.
